
    
      Participants who received treatment with namilumab in the previous study M1-1188-002-EM
      (PRIORA [NCT01317797]) will have two whole blood samples (3 mL each) collected to correlate
      genetic markers with namilumab treatment responses as determined in the previous study.

      The study will enroll approximately 14 participants who received namilumab in the previous
      study.

      â€¢ No intervention is administered in this study.

      This trial will be conducted in Bulgaria, Spain and The Netherlands. The overall time to
      participate in this study is 1 day.
    
  